BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | Aug 19, 2019
Company News

Aug. 19 Company Quick Takes: PharmaMar gets bump on FDA timeline in SCLC; plus Shionogi, Vanda and Moderna

PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the company said that based on the results of dialogue with FDA, it will submit an NDA next quarter...
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
BioCentury | Jun 7, 2018
Finance

Deerfield goes to school

...University Bluefield Innovations Nov. 2017 Up to $65 million over five years Undisclosed compounds targeting RNA polymerase I (Pol I)...
...their first funding would go to a project involving undisclosed compounds that target the enzyme RNA polymerase I (Pol I)...
...Francisco, San Francisco, Calif. Vanderbilt University, Nashville, Tenn. Weill Cornell Medicine, New York, N.Y. Targets RNA polymerase I (Pol I)...
BioCentury | Mar 2, 2018
Clinical News

Senhwa reports Phase I data for CX-5461 in hematologic malignancies

...treat breast cancer that is expected to complete by year end. CX-5461 is an oral RNA polymerase I (Pol I)...
...stabilizer. Senhwa Biosciences Inc. (TPEx:6492), New Taipei City, Taiwan Product: CX-5461 Business: Cancer Molecular target: RNA polymerase I (Pol I)...
...activity Status: Phase I data Milestone: Start Phase II (2018) Mary Romeo CX-5461 American Society of Hematology ASH Senhwa Biosciences Inc. RNA polymerase I (Pol I)...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Musculoskeletal

...Treacher Collins syndrome. TARGET/MARKER/PATHWAY: DEAD box helicase 21 (DDX21); treacle ribosome biogenesis factor 1 (TCOF1); RNA polymerase I (Pol I)...
...Wysocka, Stanford University School of Medicine, Stanford, Calif. email: wysocka@stanford.edu Claire Quang Stanford University DEAD box helicase 21 (DDX21) RNA polymerase I (Pol I) Treacle...
BioCentury | Jan 26, 2018
Clinical News

PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer

PharmaMar S.A. (Madrid:PHM) said Zepsyre lurbinectedin (PM01183, PM1183) missed the primary endpoint of improving progression-free survival (PFS) vs. topotecan or pegylated liposomal doxorubicin in the Phase III CORAIL trial to treat platinum-resistant ovarian cancer. The...
BioCentury | Jan 19, 2018
Clinical News

PharmaMar's Zepsyre misses in first Phase III trial

PharmaMar S.A. (Madrid:PHM) lost €0.88 (34%) to €1.70 on Friday after reporting that Zepsyre lurbinectedin (PM1183) missed the primary endpoint of improving progression-free survival (PFS) vs. topotecan or pegylated liposomal doxorubicin in the Phase III...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

...T cell lymphoma (CTCL). Senhwa Biosciences Inc. will have Phase I data for CX-5461, an RNA polymerase I (Pol I)...
...presented: enhancer of zeste homolog 1 (EZH1); histocompatibility minor HA-1 (HMHA1; HA-1; HLA-HA1); IL-9; and RNA polymerase I (Pol I)...
...evaluation time point," 57% CR, partial response (PR) at 24 weeks in 14 patients 3256 RNA polymerase I (Pol I)...
BioCentury | Nov 30, 2017
Clinical News

PharmaMar reports Phase II response data for Zepsyre in Ewing's sarcoma

PharmaMar S.A. (Madrid:PHM) reported data from 25 patients with Ewing’s sarcoma who received ≤2 prior chemotherapeutic treatments in a Phase II trial showing that 3.2 mg/m 2 Zepsyre lurbinectedin (PM01183, PM1183) given every 3 weeks...
Items per page:
1 - 10 of 34